Showing 4281-4290 of 8129 results for "".
- FUE Technique Shows Promise for Treating Acne Keloidalis Nuchaehttps://practicaldermatology.com/news/fue-technique-shows-promise-for-treating-acne-keloidalis-nuchae/2461963/Follicular unit excision (FUE) may help treat acne keloidalis nuchae (AKN), according to research in the Journal of The American Academy of Dermatology – JAAD Case Reports.
- European Commission Green Lights Opdivo as an Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/european-commission-green-lights-opdivo-as-an-adjuvant-treatment-for-completely-resected-stage-iib-or-iic-melanoma/2461960/The European Commission (EC) has approved Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of adults and adolescents 12 years of age and older with stage IIB or IIC melanoma who have undergone complete resection, Bristol Myers Squibb reports. The EC approval cove
- Simpson Lab Awarded $50k Grant from Foundation for Ichthyosis & Related Skin Typeshttps://practicaldermatology.com/news/simpson-lab-awarded-50k-grant-from-foundation-for-ichthyosis-related-skin-types/2461955/Cory Simpson, MD, PhD, received a one-year $50k grant from the Foundation for Ichthyosis & Related Skin Types (FIRST) to support the&
- Verrica Supports FDA’s Warning Letters to Retailers Selling Unapproved Molluscum Contagiosum Treatmentshttps://practicaldermatology.com/news/verrica-supports-fdas-warning-letters-to-retailers-selling-unapproved-molluscum-contagiosum-treatments/2461954/Verrica Pharmaceuticals Inc. supports the U.S. Food and Drug Administration’s (FDA’s) recent action against retailers and manufacturers of unapproved products for the treatment of molluscum contagiosum. “On the heels of the June 1, 2023 FDA warning to consumers not to
- Unpacking the AAD’s Updated Guidelines for Managing AD With Topical Therapies in Adultshttps://practicaldermatology.com/news/guideline-author-dr-robert-sidbury-talks-to-dermwire-about-the-new-recommendations/2461953/Despite the availability of systemic medication to treat atopic dermatitis (AD), topical treatments remain mainstays, and new ones have come to market in recent years. To keep pace with the changes, the American Academy of Dermatology (AAD) updated its 2014 guidelines for managing atopi
- Paradigm Therapeutics Acquires Late Stage "Breakthrough Therapy" for Treatment of All Subtypes of EBhttps://practicaldermatology.com/news/paradigm-therapeutics-acquires-late-stage-breakthrough-therapy-for-treatment-of-all-subtypes-of-eb/2461948/Paradigm Therapeutics Inc. now has the worldwide rights of SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics. Terms of the deal have not been disclosed. SD-101 received Rare Pediatric Disease designation&
- Sentient’s Tixel Receives FDA Nod for Treatment of Periorbital Wrinkleshttps://practicaldermatology.com/news/sentients-tixel-receives-fda-nod-for-treatment-of-periorbital-wrinkles/2461945/The device combines heat with the forward motion of a medical-grade titanium tip. The U.S. Food and Drug Administration has approved
- Business News: LEO Pharma to Acquire Timber Pharmaceuticalshttps://practicaldermatology.com/news/business-news-leo-pharma-to-acquire-timber-pharmaceuticals/2461943/LEO Pharma is set to acquire Timber Pharmaceuticals, Inc. The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million, and up to an additional $22.0 million in contingent value rights payable upon achievement o
- First Patient Dosed in Phase 1/2a Trial of AGLE-102 to Treat Severe Second-degree Burnshttps://practicaldermatology.com/news/first-patient-dosed-in-phase-12a-trial-of-agle-102-to-treat-severe-second-degree-burns/2461938/The first patient has been dosed in Aegle Therapeutics Corp.’s Phase 1/2a clinical trial of AGLE-102 for the treatment of severe second-degree burns. AGLE-102 is an investigational product comprised of native extracellular vesicles isolated from allogeneic stem cel
- Regenerative Medicine in Action: Turn Bio's ERA Technology Reprograms Skin Cellshttps://practicaldermatology.com/news/regenerative-medicine-in-action-turn-bios-era-technology-reprograms-skin-cells/2461930/Reprogramming with Turn Bio's ERA technology can rejuvenate cells within the extracellular matrix (ECM), resulting in changes related to improved skin quality and structure, according to a presentation at the AAD 2023 Innovation Academy in Tampa, Fla. ERA reprogramming tec